Sun, Jan 25, 2015, 6:27 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CryoLife Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dlhild@ymail.com dlhild Feb 4, 2010 10:10 PM Flag

    1:1 stock exchange...

    pahad21: First, read the 2008 annual report. Then, if you can understand it, we could have an enlightened discussion. You don't even understand the CRY model. Over 50% a "tissue" business (essentially a zero net income product line...by law or by design I don't know). Then BioGlue a nice high margin business with a patent problem. Then HemoStase giving them a good portion of their revenue/gross margin growth. Without the HemoStase growth, they are not growing any of their product lines very well. Non-profit model, low revenue growth, put it together and a person can understand why CRY's market cap is only about 1.7x revenue...very low for a medical products company...when this multiple is low there is a reason...and I have pretty much already explained it. Read the 2008 annual report cover to cover...you will learn a lot.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Trying to sadly bash CRY, a public company with revenue growth and proven earnings.

      But you are supporting a small non-public that hasn't been able to go public for 10 years. I'm guessing you are medafor employee or just a dope that was tricked into overpaying for his non-public shares. Or maybe the medafor founders fired you?

      Oh, and by the way, Medafor has a pathetic website, and it is 2010 afterall. But it looks like a not very bright 14 year old designed it.

 
CRY
11.74-0.05(-0.42%)Jan 23 4:02 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.